Elite Pharma, Mikah Pharma sign manufacturing, supply pact
As per the terms of the agreement, Elite will conduct the laboratory stability studies, manufacturing and packaging for two generic products: Isradipine capsules USP, 2.5mg and 5mg and
China-based IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to €423.5m ($488.3m), giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries.